Spectradyne LLC

Innovation in Nanoparticle Analysis

The company

Spectradyne LLC is commercializing a revolutionary method of measuring sub-micron nanoparticles. Applications include characterizing nanomedicine delivery systems, the measurement of protein aggregation in the drug development industry, virology and in consumer product quality control.

The Spectradyne Experimental Innovation Award

Spectradyne LLC encourages new and innovative research using its microfluidics-based nanoparticle analysis technology. We will provide eligible researchers with access to our nCS1TM instrument and cartridges through our Experimental Innovation Award competition, and provide financial support to present results obtained with this instrument at an international conference. Click here to learn more about this program.

Company founders

monzon pic

Franklin Monzon, CEO

Dr Monzon spent 14 years working in the semiconductor industry at Intel, Xponent and GCS before co-founding Spectradyne, He has broad expertise in manufacturing, product development, and business development, a PhD from Caltech and an MBA from UCLA Anderson.

fraikin pic

Jean-Luc Fraikin, Chief Scientist

Dr Fraikin developed the initial NPA technology during his PhD thesis work at UC Santa Barbara in Dr. Cleland's research group. He has worked in cancer cell biology and biochemistry, and at InDevR led prototyping efforts for a microfluidics-based molecular diagnostic platform. At Spectradyne, Dr Fraikin leads the development of instrument fluidics, software, and system integration.

meinhold pic

Peter Meinhold, Chief Engineer

Dr Meinhold is an experimental astrophysicist at UC Santa Barbara, and an expert in low noise electronics, signal analysis, and in developing compact instrumentation for space. He is proficient in extracting signals with amplitudes orders of magnitude smaller than the instrument noise. Dr Meinhold has a PhD from UC Berkeley and leads the development of instrument electronics.

cleland pic

Andrew N Cleland, Scientific and Technical Advisor

Dr Cleland is the John A MacLean Professor of Quantum Engineering Innovation at the University of Chicago, and the recipient of Science magazine's "Breakthrough of the Year" for 2010. An authority on nanotechnology, nanomechanics and quantum information, Dr. Cleland is active in device design and implementation.

News & Press Releases


May 2017 Jean-Luc Fraikin, co-founder and CTO of Spectradyne, presents at the annual meeting of the International Society for Extracellular Vesicles (ISEV) in Toronto. Spectradyne is seeing increasing interest in our measurements of EVs, or exosomes, due to the ability of our nCS1 instrument to make rapid, high-resolution size and concentration measurements of biological mixtures.

May 2017 Spectradyne exhibits at the AAPS National Biotech Conference in San Diego. Our protein aggregation, virus, and nanomedicine measurement results are a hit!

April 2017 Spectradyne's technology readily quantifies the concentration and size of nanoparticle contamination in "clean" fluids such as IV saline, saline in pre-filled syringes, and more: cleanliness of fluids.

March 2017 Nanoparticles are everywhere. As some small proof, Spectradyne measured the nanoparticle content of three Korean and three Japanese liquors. For the results of this soju vs. sake comparison, see this link.

January 2017 Spectradyne expands its concentration measurement capability below 1e6 particles/ml. Protein aggregates are detected at levels of only a few hundred thousand per milliliter!

December 2016 Sales Account Executive Lew Brown joins the Spectradyne team.

October 2016 Robust detection of particles up to 2 microns in diameter is demonstrated on multiple particle types (polystyrene, silica, protein aggregates, etc).

September 2016 Spectradyne exhibits at NanoDDS 2016 at Johns Hopkins University. Accurate sizing of synthetic nanoparticles in complex media are a strength of Spectradyne's technology.

August 2016 Spectradyne completes installation of another nCS1 instrument, at a major national government lab.

August 2016 Spectradyne exhibits at the AAPS Protein Aggregation and Immunogenicity Workshop in Breckenridge, CO. Our nCS1 instrument excels at detecting protein aggregates at high resolution, both in size and concentration: see our Applications page for more info.

June 17, 2016 Spectradyne's article "Quantitative Nanoparticle Analysis Based on Resistive Pulse Sensing" is published in American Laboratory magazine. Read the article!

June 7, 2016 Spectradyne presents its nanoparticle analysis technology at the National Science Foundation's Technology Showcase, as part of the NSF's 2016 SBIR Phase II Conference.

May 16-17, 2016 Spectradyne exhibits at the 2016 AAPS National Biotech Conference in Boston.

April 7, 2016 Spectradyne installs a nCS1 instrument at a prominent privately held biotech company. This customer's technology utilizes nanoparticles to deliver therapeutics in a highly targeted manner.

Mar. 30, 2016 Spectradyne's article "One Size Does Not Fit All: Nanoparticle Size Analysis for Nanomedicine Applications" is published in Drug Development & Delivery. Read the article.

Mar. 29-31, 2016 Spectradyne exhibits at the Spring meeting of the MRS.

Jan. 29, 2016 Spectradyne installs its nCS1 instrument at a major US medical center. The nCS1 will be used to study nanoparticles in serum, in connection with Spectradyne's Phase II NSF SBIR grant.

Jan. 21, 2016 Spectradyne installs its nCS1 instrument at a leading global developer of pharmaceuticals and vaccines.

Dec. 2, 2015 Spectradyne installs its innovative nCS1 instrument at a major global biopharmaceutical company.

Nov. 2015 Spectradyne participates the Coulter College Commercializing Innovation (C3i) program, a partnership between the Wallace H. Coulter Foundation and NIH SBIR offices.

Sept. 25, 2015 Spectradyne is awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB).

Aug. 15, 2015 Spectradyne is awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation.

July 23, 2015 Dr. Jean-Luc Fraikin gives an invited talk "The Spectradyne nCS1: A Revolutionary Tool for Sizing Submicron Particles" at Sanofi Pasteur in Toronto, Ontario.

July 17, 2015 Dr. Jason Cleveland, co-founder of Asylum Research, joins Spectradyne's Advisory Board. Dr. Cleveland co-founded Asylum, a designer/manufacturer of AFMs and served as Chairman and CEO.

August 16-18, 2015 Spectradyne exhibits in Boston at the annual meeting of the American Chemical Society.

June 8-9, 2015 Spectradyne exhibits at the AAPS NBC in San Francisco.

June 2015 Dr. Jean-Luc Fraikin gives an invited talk on "Rapid nanoparticle characterization in polydisperse samples" at the 3M Company in St. Paul, Minnesota.

May 2015 Spectradyne exhibits at the AAPS National Biotech Conference in San Francisco.

March 2015 Spectradyne introduces the fully functional nCS1 prototype at Pittcon 2015.

February 2015 Jason Stubbs, M.D. of the University of Kansas joins Spectradyne's Advisory Board.

December 2014 Spectradyne is awarded a NSF Phase IB grant.

November 2014 Spectradyne exhibits at the SoCalBio Investor & Partnership Conference.

November 2014 Spectradyne exhibits at the UCLA Advanced Materials Partnering Conference.

October 2014 Shawn Cao of Amgen joins Spectradyne's Advisory Board.

September 2014 Spectradyne is awarded a Phase I SBIR grant from the NIH.

August 2014 Robert Lee of Particle Sciences, Inc. joins Spectradyne's Advisory Board.

June 2014 Spectradyne presents at the TechConnect-National Innovation-National SBIR/STTR Summit. Winner of a National Innovation Award.

May 2014 Spectradyne is awarded a Phase I SBIR grant from the National Science Foundation.

connect with us

learn more